You Are Here    Home   News

News
Injectable cabotegravir makes progress towards human efficacy studies: doubts about injectable rilpivirine
by Gus Cairns, 2014-10-30 09:30
Researchers have determined the dose of an injectable formulation of the integrase inhibitor cabotegravir (formerly GSK744) that will be taken into efficacy trials to see if it can be used for pre-exposure prophylaxis (PrEP). Studies in animals were presented earlier this year suggesting that drug levels stayed high enough in the body for it to

Tenofovir gel use associated with lower HSV-2 risk in women
by Lesley Odendal, 2014-10-30 09:30
The risk of acquiring herpes simplex virus type 2 (HSV-2) was reduced by 46% (aIRR:0.54, 95%CI:0.30-0.97, p=0.038) among women who regularly used the vaginal gel containing tenofovir, according to a secondary analysis of the Vaginal and Oral Interventions to Control the Epidemic (VOICE) trial presented at the HIV Research for Prevention conference (R4P) in Cape Town,

Increased expenditure on social security has benefits for TB control in the EU
by Michael Carter, 2014-10-30 08:00
Increased expenditure on social protection programmes – sickness, disability and unemployment benefits, old age pensions, housing support – is associated with improved tuberculosis (TB) control, according to an analysis of data from European Union (EU) countries published in Lancet Infectious Diseases. “Social protection spending is strongly associated with lower tuberculosis case notification, incidence, and mortality rates,” comment the

Research for Prevention conference opens with real hope for an HIV vaccine
by Gus Cairns, 2014-10-29 10:50
“There’s only one Berlin patient still. But by this time next year he will at least be joined by 40-50 Portland monkeys.”  This was vaccine researcher Louis Picker, summarising in quotable form why the outlook for the development of an effective HIV vaccine is brighter than it has been for years, in a Satellite session

Second European PrEP study is closed early due to high effectiveness
by Gus Cairns, 2014-10-29 08:30
In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomised phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. The investigators of the IPERGAY trial, which has six sites in France and one in Canada, announced today a “Significant

Second European PrEP study closes placebo arm early due to high effectiveness
by Gus Cairns, 2014-10-29 08:30
In an extraordinary development, a second European scientific trial of pre-exposure prophylaxis (PrEP) has had its randomised phase closed early due to high effectiveness, just two weeks after the UK PROUD trial did exactly the same thing. The investigators of the IPERGAY trial, which has six sites in France and one in Canada, announced today a “Significant

How does a ‘human rights based approach’ work out on the ground? Lessons from South Africa
by Roger Pebody, 2014-10-29 07:10
While international rhetoric on HIV and AIDS frequently invokes human rights, putting these ideas into practice in specific settings remains challenging, according to a process evaluation of an intervention in rural South Africa published in the October issue of Culture, Health and Sexuality. Although female health volunteers understood gender inequalities to be a key

Emerging epidemic of transmitted HIV drug resistance in low- and middle-income countries, with highest burden seen in MSM
by Michael Carter, 2014-10-28 08:00
Prevalence of transmitted drug-resistant HIV has doubled in low- and middle-income countries in recent years, results of a meta-analysis published in AIDS show. Between 2004-08 and 2009-13, rates of transmitted resistance increased markedly in all key populations in these settings. The increase coincides with the expanded roll-out of antiretroviral therapy (ART) in resource-limited settings; however

Bedaquiline as part of tailored therapy for MDR- and XDR-TB achieves impressive culture conversion rates
by Michael Carter, 2014-10-27 08:30
Use of the new anti-tuberculosis (TB) drug bedaquiline as part of a tailored regimen achieved high rates of culture conversion in people with multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB), French investigators report in the online edition of Clinical Infectious Diseases. The study population comprised 35 people who were provided with compassionate access to the drug